Human papillomavirus vaccine acceptability among a national sample of adult women in the USA

Background: In the USA, the human papillomavirus (HPV) vaccine is currently licensed for 9–26-year-old females, but licensure for women over 26 years is being considered. The aim of the current study was to investigate the association of sociodemographic and health-related factors to HPV vaccine acceptability among adult women. Methods: The current study utilised a nationally representative sample of women (n = 1323) aged 27–55 living in the USA, with an oversampling of black and Latina women. A multiple item measure of HPV vaccine acceptability across varying cost and location-of-availability (clinic only v. any local pharmacy) conditions was the main outcome measure. General linear modelling was used to analyse the association of vaccine cost, location availability, and sociodemographic and health-related variables with vaccine acceptability. Results: Vaccine cost had the strongest association with acceptability [F (2, 1249) = 832.1; P